Skip to content
Screener

Operating Cash Flow at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$2.13B+51.9%
Danaher logo
DanaherDHR
$1.53B+14.6%
Repligen logo
RepligenRGEN
$32.77M+14.5%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$108.1M-16.8%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$44.27M-10.0%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$179.73M-12.2%

Other financials

Income statement

See full
Revenue$51.4M+8.5%
Gross profit$20.7M+166%
Operating income-$15.1M+77.2%
Net income-$12.4M+68.6%
EPS (diluted)-$0.08+70.4%

Balance sheet

See full
Cash & equivalents$70.6M-73.8%
Total debt$176.7M-52.4%
Total equity$204.6M-23.0%
Total assets$603.7M-32.7%

Cash flow

See full
CapEx$370.0K-87.1%
Free cash flow$3.6M+128%

Valuation

See full
Market cap$918.96M+210%
Enterprise value$1.03B+158%
P/S4.4×+3.1×

Profitability

See full
Gross margin34.9%+4.4pp
Operating margin-56.1%-21.3pp
Net margin-37.1%-13.6pp
FCF margin-17.2%

Returns & leverage

See full
Return on equity-32.9%-9.4pp
Debt / equity0.9×-0.5×
Current ratio4.1×-1.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001823239-26-000059
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Accounts payable4,3621,074
Accrued expenses and other current liabilities(3,521)6,639
Other long-term liabilities(1,893)(14,678)
Net cash provided by (used in) operating activities12,657(19,655)
Investing activities:
Cash paid for acquisitions of a business, net of cash acquired(18,990)
Purchases of property and equipment(4,807)(7,375)
Net cash used in investing activities(4,807)(26,365)

Item 1. Financial Statements

FAQ

What is Maravai LifeSciences Holdings, Inc.'s operating cash flow?
Maravai LifeSciences Holdings, Inc. (MRVI) reported operating cash flow of $3.99M in Q2 2026.
How has Maravai LifeSciences Holdings, Inc.'s operating cash flow changed year-over-year?
Maravai LifeSciences Holdings, Inc.'s operating cash flow increased by 138.9% year-over-year, from -$10.27M to $3.99M.
What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s operating cash flow?
Over 3 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s operating cash flow has grown at a -46.1% compound annual growth rate (CAGR), from $368.57M to -$57.57M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Maravai LifeSciences Holdings, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude